Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T13:43:00.721Z.
Calculation as of: 2026-10-06T13:43:00.721Z.
Quote observation: 2026-10-06T13:40:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 88e906b5462319013e69f4ee379284aaffb96e00f9acc248208650345dd3e90c
PEG RATIO
N/A
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immunovant, Inc. (IMVT) | $6.84B | N/A | N/A | N/A | N/A |
| Chemed Corporation (CHE)vs › | $6.72B | N/A | 2.98 | 2.74 | 2.10 |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.66B | N/A | N/A | N/A | N/A |
| Alkermes plc (ALKS)vs › | $7.03B | N/A | N/A | N/A | N/A |
| GRAIL Inc. (GRAL)vs › | $7.07B | N/A | N/A | N/A | N/A |
| Lantheus Holdings, Inc. (LNTH)vs › | $6.53B | N/A | 0.53 | 0.48 | 0.48 |
| Amneal Pharmaceuticals, Inc. (AMRX)vs › | $6.52B | N/A | N/A | N/A | N/A |
| Ionis Pharmaceuticals, Inc. (IONS)vs › | $7.20B | N/A | N/A | N/A | N/A |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $6.24B | N/A | N/A | N/A | N/A |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $6.11B | N/A | 0.03 | 0.06 | 0.06 |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
